In-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups
|
|
- Allen Carpenter
- 5 years ago
- Views:
Transcription
1 In-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups
2 Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) in transplant eligible patients with newly diagnosed multiple myeloma (MM): results from the EMN02/HO95 phase 3 trial
3 Methods MM patients enrolled in the RV-MM-COOP-0556 (EMN02/HO95 MM; NCT ) Newly diagnosed 65 years MRD assessement in patients achieving suspected CR before lenalidomide maintenance N: 706 N: 459 N: VCD CTX + PBSC harvest R1 HDM1-2 N: 506 R2 2 VRD N: VMP No cons Lenalidomide maintenance CR: complete response; N: number of patients ; V, bortezomib; C, cyclophosphamide; D, dexamethasone; CTX: cyclophosphamide 2-3g/mq, PBSC: peripheral stem cell collection, HDM: high dose melphalan 200mg/mq, R, lenalidomide; M, melphalan; P, prednisone; Cons: consolidation, Maint: maintenanc; Cavo M et al. ASH 2016; Abstract 673. Sonneveld P. et al. ASH 2016; Abstract 292 Pre Maint Maint Maint Maint Maint EVERY 6 MONTHS UNTIL CLINICAL RELAPSE
4 Methods MM patients enrolled in the RV-MM-COOP-0556 (EMN02/HO95 MM; NCT ) Newly diagnosed 65 years MRD assessement in patients achieving suspected CR before lenalidomide maintenance N: 706 N: 459 N: VCD CTX + PBSC harvest R1 HDM1-2 N: 506 R2 2 VRD N: VMP No cons Lenalidomide maintenance CR: complete response, N: number of patients ; V, bortezomib; C, cyclophosphamide; D, dexamethasone; CTX: cyclophosphamide 2-3g/mq, PBSC: peripheral stem cell collection, HDM: high dose melphalan 200mg/mq, R, lenalidomide; M, melphalan; P, prednisone; Cons: consolidation, Maint: maintenanc; Cavo M et al. ASH 2016; Abstract 673. Sonneveld P. et al. ASH 2016; Abstract 292 Pre Maint Maint Maint Maint Maint EVERY 6 MONTHS UNTIL CLINICAL RELAPSE
5 Methods Sample logistics in the EMNO2 MRD study Samples were centralized in 3 laboratories from 10 countries 2 workshops: 1) Orlando, (ASH) December ) Rotterdam, May 2016 Brno, Czech republic Rotterdam, The Netherlands Turin, Italy
6 Tube 1: Tube 2: Methods - Sampling: bone marrow - Processation: within hours - Preparation: Bulk-lysis protocol (EuroFlow) -Data acquisition: 2 x 10 6 leucocytes or 1 x 10 4 plasma cells - Cut-off for MRD positivity: 20 clonal plasma cells - Maximal sensitivity: 1 x 10-5 Brno, Czech republic Rotterdam, The Netherlands Turin, Italy van Dongen JJ et al. Leukemia Sep;26(9): Kalina T et al. Leukemia Sep;26(9):
7 Results Quality checks were done among the 3 European laboratories to compare sensitivity and to show correlation between protocols Hofste op Bruinink D et al. ASH 2016; Poster 2072
8 Age Median, yrs Range (IQR) ISS stage at diagnosis, N (%) I II III FISH RISK, N (%) Standard High Missing Random A, N (%) HDM1-2 VMP Random B, N (%) VRD no consolidation off Results Patient characteristics (n = 316) (44) 120 (38) 57 (18) 186 (52) 70 (22) 60 (19) 199 (63) 117 (37) 160 (51) 144 (46) 12 (3) IQR: interquartile range, ISS: International Staging System, FISH : fluorescence in situ hybridization, standard risk : del17 and t(4;14) and t(14; 16) negative, High risk: del17 and/or t(4;14) and/or t(14; 16) positive
9 Results MRD status at pre-maintenance Sub-analysis on MRD positive patients at pre-maintenance who had a second MRD evaluation >1 year of Lenalidomide % 24% MRD positive Pre maintenance MRD positive MRD negative % of patients % 52% LEN maintenance 6-12 months
10 Results MRD status during maintenance Sub-analysis on MRD positive patients at pre-maintenance who had a second MRD evaluation >1 year of Lenalidomide 100 4% months MRD positive Pre maintenance % of patients % 52% 6-12 months 0 LEN maintenance MRD negative
11 Results Progression free Survival: Median Follow-Up from MRD enrollement of 33 Months yr PFS 77% Progression-free survival N = 316 MRD negative MRD positive Median PFS NR 38 months 52% 0.00 HR (95% CI) P value 0.33 ( ) < Numbers at risk MRD Negative MRD Positive Months
12 Results PFS by Random 1 VCD-ASCT vs VCD-VMP 1.00 Progression-free survival (%) Time (months) Number at risk ASCT VMP ASCT VMP ASCT VMP PFS median, mos NR 42.5 PFS at 3 yrs, % Cavo M et al. ASH 2016; Abstract 673. Cavo M et al. ASCO 2017; Abstract
13 Results Indipendence from treatment MRD for ARM A MRD for ARM B Progression-free survival Progression-free survival Numbers at risk MRD Negative MRD Positive MRD negative MRD positive P= Months MRD negative MRD positive P= Months
14 Results Landmark analysis at 1 year of len maintenance VCD-int- ± cons Lenalidomide Continuous Therapy yr PFS Progression-free survival MRD negative MRD positive 92% 65% 0.00 P< Months Preliminary results: Longer follow-up needed Int: intensification; Cons: consolidation 85% were persistent MRD negative (first negativity pre-maintenance)
15 Results Multivariable Cox analysis for PFS HR (95% CI) p value MRD Negative vs Positive 0.33 ( ) < ISS II vs III 0.71 ( ) I vs III 0.39 ( ) Citogenetic Risk Standard vs High 0.34 ( ) < Age >60 vs ( ) Sex Female vs Male 1.27 ( ) Lower risk of progression/death Higher risk of progression/death * Adjusted for random therapies
16 Results Subgroup analyses for PFS HR (95% CI) Interaction-p Overall 0.33 ( ) ISS I 0.51 ( ) II 0.39 ( ) III 0.07 ( ) Citogenetic Risk Standard 0.64 ( ) High 0.11 ( ) Age ( ) > ( ) Sex Female 0.27 ( ) Male 0.38 ( ) Lower risk for MRD - * Adjusted for random therapies
17 Results Subgroup analyses for PFS: High Risk patients and MRD FISH HIGH RISK ISS III Progression-free survival yr PFS 79% 27% FISH High-MRD Neg FISH High-MRD pos Progression-free survival % 33% 2-yr PFS ISS III-MRD pos ISS III-MRD Neg Months Months Del17p : 25 patients; 8/9 MRD + relapsed, 5/16 (31%) MRD- relapsed t (4; 14): 41 patients; 5/6 MRD + relapsed, 10/35 (28) MRD - relapsed t (14; 16): 10 patients, all MRD - at pre-maintenance
18 Conclusions MRD by MFC is a strong prognostic factor in MM patients receiving intensification with novel agents or transplant During Lenalidomide maintenance 48% of MRD positive patients with at least one evaluation after 1 year of therapy became MRD-negative The achievement of MRD negativity suggest the importance of deep response in high-risk MM patients defined by FISH abnormalities and ISS stage
19 Acknowledgments Divisione di Ematologia 1 Azienda Ospedaliero Universitaria Citta della Salute e della Scienza, Torino, Italy. Prof. Mario Boccadoro Prof. Antonio Palumbo Dr. Sara Bringhen Dr. Alessandra Larocca Dr. Francesca Gay Dr. Mariella Genuardi Babak Myeloma Group, Masaryk University, Brno, Czech Republic Prof. Roman Hajek Transplant Unit, nurses, patients and all participating centers Data Managing Staff Department of Hematology, Erasmus Universisty Medical Center, Rotterdam, Netherlands Prof. Pieter Sonneveld Dr. Davine Hofste op Bruinink Cytofluorimetric laboratories: Turin: Paola Omedé, Milena Gilestro, Vittorio Muccio, Elona Saraci Rotterdam: Vincent Van der Velden Brno: Lucie Říhová Statisticians: Stefano Spada and Bronno Van der Holt
20 EMN-02 MRD Workshop. Rotterdam, The Netherlands May 2016 Thank you!
Highlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationDisclosures for Alessandra Larocca, MD
Disclosures for Alessandra Larocca, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria No relevant conflicts of interest to declare No relevant conflicts of interest
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationRisk of Second Primary Malignancies (SPMs) Following. Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3
ASH2933 Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)
More informationAperTO - Archivio Istituzionale Open Access dell'università di Torino
AperTO - Archivio Istituzionale Open Access dell'università di Torino Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationWhat New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationGIMEMA NMSG DSMM CEMSG
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationSUPPLEMENTARY APPENDIX
SUPPLEMENTARY APPENDIX The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network Niels W.C.J.
More informationSTUDY DESIGN. VMP 6-week cycles, total of 9 cycles. Figure 2. Alcyone study design. Countries housing study sites are shaded in gold.
TPS8608 A Randomized Open-label Study of Bortezomib, Melphalan, And Prednisone (VMP) Versus Daratumumab () Plus VMP in Patients With Previously Untreated Multiple Myeloma (MM) Who Are Ineligible for High-dose
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationTherapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz
Therapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz 15.6.218 Newly Diagnosed Multiple Myeloma Transplant Eligible NDMM TE VCD is preferable to
More informationAutologous Hematopoietic Stem Cell Transplantation and Mobilization in Multiple Myeloma:
Autologous Hematopoietic Stem Cell Transplantation and Mobilization in Multiple Myeloma: Current Debate and Developments This transcript has been edited for style and clarity and includes all slides from
More information"Chemotherapy based stem cell mobilization: pro and con"
"Chemotherapy based stem cell mobilization: pro and con" Mohamad MOHTY Clinical Hematology and Cellular Therapy Dpt. Sorbonne Université Hôpital Saint Antoine Paris, France Disclosures Sponsorship or research
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationmsmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma
msmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma msmart Multiple myeloma is increasingly recognized as more than one disease, characterized by marked cytogenetic,
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More information2015 Updates in Multiple Myeloma
2015 Updates in Multiple Myeloma Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma and Myeloma Blood and Marrow Transplantation Program The University of Kansas Medical Center 1 Earliest
More informationFront-line treatment in young. Role of maintenance therapy. Rome 2017 Prof Le Gouill S.
Front-line treatment in young patients with MCL: Role of maintenance therapy Rome 2017 Prof Le Gouill S. Is there a need for maintenance for young MCL patients? Is there a need for maintenance for young
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationMultiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016
Multiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016 Key Features of Myeloma Biology Myeloma is not one disease 1 At least 7 subtypes based
More informationTopics. When to treat? Smoldering vs Symptomatic Choice of Induction regimen Role of HDT Role of consolidation/maintenance
Initial Therapy Sagar Lonial, MD Chair and Professor Department of Hematology and Medical Oncology Chief Medical Officer, Winship Cancer Institute Emory University School of Medicine Topics When to treat?
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationAutotrapianto singolo o doppio nel mieloma: è ancora lo standard?
Azienda Ospedaliera Universitaria Ospedali Riuni4 di Foggia Autotrapianto singolo o doppio nel mieloma: è ancora lo standard? Silvana F. Capalbo UOC Ematologia e Trapianto di Cellule Staminali Emopoie?che
More information